Key Developments: Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

29 Jul 2014
Price Change (% chg)

$-0.18 (-0.42%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Abbott Laboratories raises FY 2014 guidance
Thursday, 8 May 2014 03:00am EDT 

Abbott Laboratories:Sees FY 2014 revenue, is expected to equal about DKK 2.4 billion.Sees FY 2014 EBITDA about DKK 425 million.  Full Article

Abbott Laboratories's MitraClip Device now approved in Canada
Wednesday, 30 Apr 2014 08:01am EDT 

Abbott Laboratories:Says its MitraClip therapy has received Health Canada approval, with a treatment option that can significantly improve symptoms, disease progression and quality of life for certain people with a heart condition called mitral regurgitation.Treatment with the MitraClip device can be effective in reducing the symptoms associated with severe MR, such as shortness of breath and fatigue, which may help people lead a more active lifestyle.  Full Article

Court of Appeals affirmed district court's decision on Glenmark Pharmaceuticals Ltd's appeal to invalidate Abbott Laboratories' TARKA
Tuesday, 22 Apr 2014 12:00am EDT 

Glenmark Pharmaceuticals Ltd:Says it loses its appeal to invalidate Abbott Laboratories' TARKA (trandolapril/verapamil hydrochloride) patent.Court of Appeals for the Federal Circuit, USA affirmed the district court's decision on April 22 regarding Glenmark's marketing of a generic equivalent of TARKA.  Full Article

Abbott Laboratories reaffirms FY 2014 EPS outlook
Wednesday, 16 Apr 2014 07:30am EDT 

Abbott Laboratories:Confirms FY 2014 earnings-per-share guidance of $2.16 to $2.26.FY 2014 EPS of $2.20 - Thomson Reuters I/B/E/S.  Full Article

Abbott announces FDA clearance for a new test to help physicians quickly and accurately diagnose diabetes
Monday, 14 Apr 2014 09:00am EDT 

Abbott Laboratories:Says that its new ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test - which can aid physicians in diagnosing and monitoring diabetes and identifying people at risk for the disease - has received 510 clearance from the U.S. Food and Drug Administration.  Full Article

Abbott Laboratories completes enrollment of Absorb randomized clinical trials in United States, Japan and China
Thursday, 10 Apr 2014 08:30am EDT 

Abbott Laboratories:Completes enrollment of three clinical trials to support approvals of Absorb Bioresorbable Vascular Scaffold (BVS) in the United States, Japan and China.  Full Article

Abbott Laboratories declares 361st consecutive quarterly dividend
Friday, 21 Feb 2014 11:50am EST 

Abbott Laboratories:Declared a quarterly common dividend of $0.22 per share.Payable May 15, to shareholders of record on April 15.  Full Article

Abbott Laboratories issues FY 2014 EPS guidance in line with analysts' estimates
Wednesday, 22 Jan 2014 07:44am EST 

Abbott Laboratories:Expects FY 2014 EPS in the range of $2.16-$2.26, representing double-digit growth at the mid-point of the guidance range.FY 2014 EPS of $2.21 - Thomson Reuters I/B/E/S.  Full Article

U.S. FDA Approves Abbott Laboratories's Device For Leaking Heart Valve-Reuters
Friday, 25 Oct 2013 12:33pm EDT 

Reuters reported that the U.S. Food and Drug Administration has approved Abbott Laboratories's MitraClip medical device, used to stop heart valve leakage in patients deemed unable to endure valve repair through open heart surgery, the Company said on October 25, 2013. The MitraClip treats mitral regurgitation, a condition in which the mitral valve of the heart does not close properly, causing blood leakage that can lead to stroke, heart attack or even death. It has estimated the disorder affects about one in 10 people aged 75 and older.  Full Article

Abbott Laboratories Announces Dividend
Wednesday, 16 Oct 2013 07:44am EDT 

Abbott Laboratories announced an increase in the company's quarterly common dividend to $0.22 per share from $0.14 per share, representing an increase of 57%. The change takes effect with the dividend that will be paid on Feb. 15, 2014, to shareholders of record at the close of business on Jan. 15, 2014. This will mark the 42nd consecutive year Abbott has increased its dividend.  Full Article


Abbott beats profit estimate, infant formulas rebound

- Abbott Laboratories Inc reported better-than-expected quarterly earnings on Wednesday as demand for its recently-recalled infant formulas began to recover and profit margins improved for other business segments.

Search Stocks